Drug Approval | February 22, 2022
The facility will manufacture its Herceptin biosimilar, Tuznue
It meets stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for Covid-19
The GMP certificate is valid for three years until April 2024.
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The company plans to collaborate with European medical centres to expand adoption of its robotic microsurgery platform
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions
Subscribe To Our Newsletter & Stay Updated
